Non-small cell lung cancer (NSCLC) trials

AI-generated summary

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer is being studied. Conditions: Advanced Lung Cancer • Eligibility: Inclusion Criteria: * Aged ≥18 years at the time of giving informed consent. * Histological or cytological confirmed unresectable advanced/metastatic lung cancer. Histological classification may be based on…. Goal: This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody, in participants with advanced/metastatic or relapsed/progressive small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC). Phase/Status/Sponsor: Unknown phase; RECRUITING; BioNTech SE.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

BBO-11818 in Adult Subjects With KRAS Mutant Cancer is being studied. Conditions: Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma +11 • Eligibility: Inclusion Criteria: * Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation *…. Goal: A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) is being studied. Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer +27 • Eligibility: Inclusion Criteria: * At least 18 years of age or 12 to 17 years of age after Safety Review Committee approval. * Locally advanced or metastatic solid malignancy…. Goal: The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; PMV Pharmaceuticals, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss is being studied. Conditions: Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant +4 • Eligibility: Inclusion Criteria: * Has a tumor with a confirmed MTAP loss * Is ≥18 years of age at the time of signature of the main study ICF *…. Goal: This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tango Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors is being studied. Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer +6 • Eligibility: Inclusion Criteria: 1. Adult participants must be 18 years of age or older 2. Advanced or metastatic solid tumors excluding primary central nervous system (CNS) tumors 3. For…. Goal: The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; IDEAYA Biosciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients is being studied. Conditions: NSCLC • Eligibility: Inclusion Criteria: * Age ≥ 18 years of age at time of consent * ECOG performance status score of ≤2 * Advanced non-small cell lung cancer to meet…. Goal: This is a Single arm, Simon's two stage pilot study in which patients with Non-Small Cell Lung Cancer (NSCLC) with metastatic disease 2L and beyond will receive OncoChoice-informed chemotherapy following National Cancer Care Network (NCCN) treatment guidelines on dosage and scheduling for NSCLC FDA approved drugs. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Illinois at Chicago.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations is being studied. Conditions: Non Small Cell Lung Carcinoma • Eligibility: Inclusion Criteria: * Must have histologically documented non-squamous (NSq) non small cell lung carcinoma (NSCLC) that is locally advanced or metastatic will be enrolled into the study. *…. Goal: Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) immune checkpoint inhibitor to adult participants to treat NSCLC. Phase/Status/Sponsor: Unknown phase; RECRUITING; AbbVie.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing is being studied. Conditions: Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Locally Advanced Non Small Cell Lung Cancer +7 • Eligibility: * INCLUSION CRITERIA: * Participants with a locally advanced or metastatic pathologically confirmed cancer whose NCI Licensed Independent Practitioner (LIP) determined they are candidates for treatment with atezolizumab,…. Goal: Background: A type of drug called monoclonal antibody immune checkpoint inhibitors are often used in cancer treatment. These drugs help the body s immune system fight cancer by blocking proteins that cause cancer cells to grow. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling is being studied. Conditions: Brest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult +5 • Eligibility: Phase 1 (Common Cancer Early Detection - CCANED) Inclusion Criteria: * Age: Adults aged 40 years or older. * Confirmed diagnosis of one of the following common cancers:…. Goal: The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients. This two-phase, multi-center observational study aims to identify specific transcriptomic biomarkers in platelets and immune cells that distinguish cancer patients from healthy individuals and correlate with treatment outcomes. Phase/Status/Sponsor: Unknown phase; RECRUITING; Javier Toledo.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers is being studied. Conditions: Advanced Breast Cancer, Advanced Gastric Cancer, Advanced Urothelial Cancer +1 • Eligibility: Inclusion Criteria: 1. Patients must have signed a written informed consent form prior to any trial specific procedures; 2. Patients must be ≥18 years old; 3. Histologically confirmed…. Goal: International study that will evaluate the association of prespecified biomarkers with resistance to Antibody-drug conjugates (ADCs), a type of targeted cancer treatment currently used in clinical practice for treating different tumor types. Phase/Status/Sponsor: Unknown phase; RECRUITING; UNICANCER.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests GV20-0251 to see if it is safe in adults with advanced or refractory solid tumors. It is a single-center, single-arm early-stage trial at West China Hospital. It uses a 3+3 dose-escalation design, starting with 10 mg/kg and 20 mg/kg given every three weeks, to find a tolerable dose and watch for dose-limiting toxicities. The trial covers multiple solid tumor types to learn about safety and dosing across indications. Key exclusions include active infections, certain heart problems or QT prolongation, autoimmune disease needing immunosuppressive therapy, HIV/HBV/HCV infections, pregnancy, and recent major surgery.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer（NSCLC） is being studied. Conditions: NSCLC, Neoadjuvant Therapy • Eligibility: Inclusion Criteria: 1. pathologically diagnosed non-small cell lung cancer 2. The treatment plan is：receiving neoadjuvant chemo-immunotherapy during the study period, followed by surgical resection Exclusion Criteria: 1. recurrent…. Goal: This observational study aims to construct and validate the performance of a multimodal predictive model in forecasting the outcomes of neoadjuvant therapy in patients with NSCLC. The core research question is: Can a multi-model approach predict outcomes of neoadjuvant therapy for non-small cell lung cancer and provide clinical recommendations? Phase/Status/Sponsor: Unknown phase; RECRUITING; Qian Chu.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors is being studied. Conditions: Cervical Cancer, Breast Cancer, Colon Cancer +4 • Eligibility: 1. Adult participants (age ≥ 18 years old) with any of the following advanced or metastatic solid tumors (documented history of histologically confirmed diagnosis): 1. Metastatic castration-resistant prostate…. Goal: A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors Phase/Status/Sponsor: Unknown phase; RECRUITING; Orano Med LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

HC010 in First-line PD-L1 Positive Advanced NSCLC Patients is being studied. Conditions: NSCLC • Eligibility: Inclusion Criteria: * 1\. Voluntarily participate in the study, communicate well with investigators, understand and voluntarily complete the study process according to this protocol, and sign the informed…. Goal: Phase 2 clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity profile of HC010 for injection in patients with positive PD-L1 (TPS ≥1%) Phase/Status/Sponsor: Unknown phase; RECRUITING; HC Biopharma Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung is being studied. Conditions: Cancer, Lung, Metastasis • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years of age. 2. Histologically proven diagnosis of cancer. At a minimum, the lung tumor in consideration for treatment must be clinically…. Goal: The objective of this study is to enhance the safety profile of SAbR in ultra-central tumors of the lung (primary or metastatic) without compromising its effectiveness. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Texas Southwestern Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry is being studied. Conditions: Cancer, Metastatic, Cancer, Cancer of Pancreas +40 • Eligibility: Inclusion Criteria: * Pts with solid and hematological malignancies; * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2,…. Goal: International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention. Phase/Status/Sponsor: Unknown phase; RECRUITING; Massive Bio, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors is being studied. Conditions: Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma +8 • Eligibility: Inclusion Criteria: 1. Subject has provided informed consent/assent prior to initiation of any study specific activities/procedures. 2. Subjects ≥ 18 years of age at the time of signing…. Goal: Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites. I) After lead in of 10 patients demonstrating safety of treatment, allow for expansion to cranial sites of disease (N=6-10) with continued enrollment in main cohort II) If toxicity criteria is not met in concurrent RT tarlatamab cohort, we will continue with sequential RT, either A) delivered within 7 days prior to cycle 1 day 1, or B) delivered during cycle 1 -2 but with pre- and post-RT washout of 7 days with no drug during RT, to examine safety in a temporally spaced setting. Phase/Status/Sponsor: Unknown phase; RECRUITING; University of Arizona.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of NX-1607 in Adults With Advanced Malignancies is being studied. Conditions: Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer +11 • Eligibility: Key Inclusion Criteria: * Age ≥ 18 years. * Measurable disease per disease-specific response criteria. * Patients must have disease that is metastatic or unresectable and have received…. Goal: This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies. Phase/Status/Sponsor: Unknown phase; RECRUITING; Nurix Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. is being studied. Conditions: Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung • Eligibility: Inclusion Criteria: * Histological or cytological diagnosis of advanced, unresectable, and/or metastatic or relapsed/refractory solid tumor. ECOG PS 0 or 1 * Presence of at least 1 measurable…. Goal: The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. Phase/Status/Sponsor: Unknown phase; RECRUITING; Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Sigvotatug Vedotin in Advanced Solid Tumors is being studied. Conditions: Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms +9 • Eligibility: Inclusion Criteria: * Disease indication * Participants must have histologically or cytologically confirmed metastatic or unresectable solid malignancy within one of the tumor types listed below (dependent on…. Goal: This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. Phase/Status/Sponsor: Unknown phase; RECRUITING; Seagen, a wholly owned subsidiary of Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments is being studied. Conditions: Non-small Cell Lung Cancer (NSCLC) • Eligibility: Inclusion Criteria: Patients * Aged ≥18 years at the time of enrollment in the study * Resident of the US, Germany, or Japan * Able to read, speak,…. Goal: The purpose of this study is to investigate the perspectives and preferences of patients and healthcare professionals (medical oncologists, pneumologists, thoracic surgeons) regarding treatment options in the resectable non-small cell lung cancer (NSCLC) setting Phase/Status/Sponsor: Unknown phase; RECRUITING; Bristol-Myers Squibb.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases is being studied. Conditions: Brain Metastases, Tumor • Eligibility: Inclusion Criteria: Patients are eligible to be included in the study only if all the following criteria apply: 1. Male/female patients who are at least 18 years of…. Goal: This is a single-center, open-label, multi-cohort Phase II study evaluating the efficacy and safety of pembrolizumab in combination with lenvatinib in patients with solid tumors and brain metastases. The study will be comprised of 3 patient cohorts: triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and solid tumor types other than TNBC and NSCLC. Phase/Status/Sponsor: Unknown phase; RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Purpose of This Study is to Evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Monotherapy in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC) is being studied. Conditions: Non-small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Agrees to follow the trial protocol and visit schedule, has signed informed consent; 2. Subjects must be ≥18 years of age at time of informed…. Goal: This is a first-in-human, single-arm, open-label, dose escalation prospective phase I clinical study to evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Alone in patients with Unresectable, Metastatic or Advanced pancreatic cancer or Non-small Cell Lung Cancer(NSCLC) after Standard Treatment Failure. The primary objective is to evaluate the safety and tolerability of TMT101 Injection as monotherapy in patients with advanced pancreatic cancer and NSCLC, and to determine the recommended therapeutic dose (RD) of TMT101 Injection as monotherapy Phase/Status/Sponsor: Unknown phase; RECRUITING; Peking Union Medical College Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Beta-only IL-2 ImmunoTherapY Study is being studied. Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma +34 • Eligibility: Key Inclusion Criteria: 1. Aged at least 18 years (inclusive at the time of informed consent). 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.…. Goal: This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Medicenna Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors is being studied. Conditions: Solid Tumors, Advanced Cancer, Renal Cancer +15 • Eligibility: Major Inclusion Criteria: 1. Men and women 18 years of age or older. 2. 9 cohorts will be enrolled: * Cohort A1 / Exon 14 NSCLC MET inhibitor…. Goal: To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET * efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistance with MET amplification and disease progression after documented CR or PR with 1st line EGFR inhibitors (EGFR-I) Phase/Status/Sponsor: Unknown phase; RECRUITING; Apollomics Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC is being studied. Conditions: Non-Small Cell Lung Cancer With EGFR Mutation • Eligibility: Inclusion Criteria: * Both sexes * ≥ 18 years old * Pathologically confirmed diagnosis of NSCLC * Stage IIIB - IV by the American Joint Committee of Cancer…. Goal: This open-label randomized clinical trial aims to evaluate the glutamine plus Lactobacillus reuteri supplementation effect in a standard-of-care diet in EGFR mutant patients with advanced non-small cell lung cancer (NSCLC) under tyrosine kinase inhibitors (TKIs) therapy. The main question it aims to answer is ¿What is the effect of glutamine plus L. Phase/Status/Sponsor: Unknown phase; RECRUITING; Instituto Nacional de Cancerologia de Mexico.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of LP-184 in Patients With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, GBM +4 • Eligibility: Patient Inclusion Criteria: 1. ≥18 years of age at the time of consent 2. Provided signed written ICF and voluntary consent prior to any mandatory study-specific procedures, sampling,…. Goal: The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available. The secondary objectives are to characterize the PK of LP-184 and its metabolites in plasma and assess clinical activity of LP-184. Phase/Status/Sponsor: Unknown phase; RECRUITING; Lantern Pharma Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies is being studied. Conditions: Non Small Cell Lung Cancer, Lung Cancer • Eligibility: Inclusion Criteria: * Patient ≥70 years * Non-small-cell lung cancer for which the multidisciplinary consultation required systemic treatment regardless of Tumor-Node-Metastasis (TNM) stage * Patient naïve to systemic…. Goal: The objective of the study is to prospectively generate real-life data in patients aged ≥70 years treated in first line for a thoracic tumor (Non-Small-Cell Lung Carcinoma) according to best standard of care as defined by the European Society for Medical Oncology (ESMO). This cohort will aim to: * characterize participants in terms of geriatrics, biology and carcinology * describe the treatment modalities by stage, as well as the results in terms of efficacy, safety and impact on quality of life. Phase/Status/Sponsor: Unknown phase; RECRUITING; GFPC Investigation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of MT-4561 in Patients With Various Advanced Solid Tumors is being studied. Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer +13 • Eligibility: Main Inclusion Criteria: Patients who have failed at least 1 prior therapy and, who have no standard treatment options demonstrated to provide clinical benefit or who are intolerable…. Goal: This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tanabe Pharma America, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer is being studied. Conditions: Unresectable Melanoma, Metastatic Melanoma, Stage III Non-small Cell Lung Cancer +1 • Eligibility: Inclusion Criteria: 1. Participants must have a confirmed diagnosis of Stage IIIC, IIID, or IV unresectable or metastatic melanoma or Stage III or IV NSCLC. 2. Participants who…. Goal: This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC). Phase/Status/Sponsor: Unknown phase; RECRUITING; Iovance Biotherapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib is being studied. Conditions: Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor • Eligibility: Inclusion Criteria: 1. Male or female, ≥ 18 years of age 2. Established histological diagnosis of advanced NSCLC, not suitable for radical treatment, with an EGFR actionable mutation…. Goal: To determine whether in patients with EGFR mutated advanced NSCLC and osimertinib as first-line treatment, the (repeated) use of LAT to ≤ 3 OP lesions and continuation of first-line osimertinib, improves the median progression-free survival by more than 3 months (i.e. PFS2-PFS1 = \>3 months). Phase/Status/Sponsor: Unknown phase; RECRUITING; Universitaire Ziekenhuizen KU Leuven.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC is being studied. Conditions: Lung Cancer, NSCLC, NSCLC Stage IV • Eligibility: Inclusion Criteria: * Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent * Patients…. Goal: To test whether it is feasible to perform the 3D-EX functional predictive response bioassay in the context of patients with advanced/metastatic NSCLC receiving immune checkpoint inhibitors in the standard of care clinical setting. Phase/Status/Sponsor: Unknown phase; RECRUITING; Jun Zhang, MD, PhD.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC is being studied. Conditions: Non-small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Written informed consent must be signed before implementing any enrollment-related procedures; 2. Age ≥18 years old; 3. Patients with histologically or cytologically confirmed stage IIA-IIIC…. Goal: This is a prospective cohort study, which aims to evaluate the effectiveness and superiority of a novel minimal residual disease-guided prognosis monitoring and adjuvant treatment in stage IIA-IIIC non-small cell lung cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; Jiangsu Cancer Institute & Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Exercise in Extended Oncogene Addicted Lung Cancer in Active Treatment is being studied. Conditions: Non-Small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Age 18 years or older 2. Willingness to provide written informed consent. 3. Life expectancy \>12 weeks. 4. Eastern Cooperative Oncology Group (ECOG) performance status…. Goal: This is an interventional, non-pharmacologic, randomized controlled study evaluating the impact on quality of life of a personalized exercise program in oncogene addicted lung cancer patients undergoing active treatment. Patients will be randomized 1:1 in two arms: arm A (interventional) and arm B (control). Phase/Status/Sponsor: Unknown phase; RECRUITING; AUSL Romagna Rimini.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumor, Adult Solid Tumor, Adult Disease +5 • Eligibility: Inclusion Criteria: * Males and nonpregnant and non-breastfeeding females, aged ≥ 18 years of age at the time of signing the informed consent. * Subjects with advanced solid…. Goal: The purpose of this study is to test the safety and therapeutic effect of TT125-802 (single agent) in subjects with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; TOLREMO therapeutics AG.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) is being studied. Conditions: Non Small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Have a full understanding of the study content, process, and possible adverse reactions before the study, and sign the informed consent form (ICF); voluntarily participate…. Goal: The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Henlius Biotech.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Quantifying Systemic Immunosuppression to Personalize Cancer Therapy is being studied. Conditions: Melanoma, Breast Cancer, Renal Cell Carcinoma +4 • Eligibility: Inclusion Criteria * Histologically documented diagnosis of metastatic/locally advanced melanoma, hormone-refractory breast cancer, RCC and UC, SCCHN, SCC or NSCLC, stage III resectable NSCLC will also be included…. Goal: The Serpentine (Stratify cancER PatiENTs by ImmuNosupprEssion) project, represents the most consistent effort so far attempted to translate MDSC into clinical practise by producing an off-the-shelf compliant assay for quantifying these cells in peripheral blood. Phase/Status/Sponsor: Unknown phase; RECRUITING; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) is being studied. Conditions: Non-small Cell Lung Cancer (NSCLC) • Eligibility: Inclusion Criteria * Participants must have a histologically- or cytologically-confirmed diagnoses of non-small cell lung cancer (NSCLC) with unresectable Stage III disease. * Participants must have received at…. Goal: A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC) Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Bristol-Myers Squibb.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumors • Eligibility: Inclusion Criteria: * Participants have histologically proven advanced solid tumors with known prevalent and high Ly6E expression, Disease characteristic: Participants should have an unresectable locally advanced or metastatic…. Goal: The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expression, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), epithelial ovarian carcinoma (EOC), squamous cell carcinoma of the head and neck (SCCHN), pancreatic ductal adenocarcinoma (PDAC), and gastric cancer (GC). Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; EMD Serono Research & Development Institute, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk Factors is being studied. Conditions: NSCLC • Eligibility: Inclusion Criteria: \- 1.Age ≥18 years, male or female. 2.ECOG Performance Status (PS) score: 0-1. 3.Expected survival ≥12 weeks. 4.Histologically or cytologically confirmed non-small cell lung cancer. 5.ALK-positive…. Goal: The primary objective is to evaluate the efficacy and safety of Iruplinalkib Tablets as postoperative adjuvant therapy in patients with stage IA, ALK-positive NSCLC with high-risk factors. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Tianjin Medical University Cancer Institute and Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC is being studied. Conditions: Non Small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Patients with stage III non-small cell lung cancer were confirmed by imaging and histological biopsy 2. Age≥ 18 3. ECOG PS:0-1 4. Tumor molecular testing…. Goal: The goal of this prospective, observational study is to explore the value of dynamic monitoring of minimal residual lesions in driver mutated stage III NSCLC for disease recurrence and prognosis assessment. The main question it aims to answer is: 1\) Whether MRD(Minimal residual disease) status can predict recurrence events in stage III driven-mutant NSCLC in advance Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Chest Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Compare the Prognostic Differences Between SBRT and Surgery for NSCLC Patients With Interlobular Fissure Invasion. is being studied. Conditions: NSCLC, Radiotherapy, Surgery • Eligibility: Inclusion Criteria: 1. Voluntarily participate and sign an informed consent form in writing; 2. Age 18 and above, regardless of gender; 3. Diagnosed as primary lung cancer through…. Goal: The goal of this observational study is to compare the prognostic differences between SBRT and Surgery for NSCLC patients with interlobular fissure invasion. The main questions it aims to answer are: 1. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tianjin Medical University Cancer Institute and Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker is being studied. Conditions: Lazertinib • Eligibility: Inclusion Criteria: 1. Histologically confirmed patients with locally progressive or metastatic non-small cell lung cancer (IIIB or IV) who have not been diagnosed as squamous cell carcinoma. 2.…. Goal: Using gefitinib or Osimertinib, an EGFR tyrosine kinase inhibitor (TKI), in patients with active mutations in epithelial cell growth factor receptors (EGFR), 70% response rate (CR+PR) and 90% disease control rate (CR+PR+SD) compared to the current non-small cell therapy, which is significant in the EFRT treatment. However, resistance causes recurrence in most patients. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Center, Korea.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors is being studied. Conditions: Melanoma, Non Small Cell Lung Cancer, Cervical Carcinoma • Eligibility: Inclusion Criteria: 1. AJCC (V8) stage III or IV melanoma, non-small cell lung cancer, cervical cancer and other solid tumors (confirmed by histology) for which existing treatment is…. Goal: This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM103 Injection in patients with advanced solid tumors. The purpose of this study is to evaluate the safety and tolerability, antitumor activity and immunoreactivity. Phase/Status/Sponsor: Unknown phase; RECRUITING; Suzhou BlueHorse Therapeutics Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumors, Non Small Cell Lung Cancer, Small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years old. 2. Inclusion criteria for the study population： Phase 1: Advanced Solid tumors. Phase 2: Extensive-stage SCLC, Non-AGA NSCLC, EGFR mutation…. Goal: This study was designed to evaluate the efficacy and safety of YL201 in combination with Ivonescimab (AK112) in subjects with solid tumor. Phase/Status/Sponsor: Unknown phase; RECRUITING; MediLink Therapeutics (Suzhou) Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors is being studied. Conditions: Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC) +6 • Eligibility: Inclusion Criteria: Part A, B, and C: * Written informed consent, dated and signed by the patient prior to any study-specific procedure. * Part B and C are…. Goal: The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of \[68Ga\]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC); Part B: is to determine the recommended phase 2 dose (RP2D) \[maximum tolerated dose (MTD) or lower dose\] for \[177Lu\]Lu-DPI-4452 for each tumor type such as ccRCC, PDAC, CRC, and urothelial carcinoma (UC); Part C: is to evaluate the preliminary antitumor activity of \[177Lu\]Lu-DPI-4452 as monotherapy for each tumor type such as ccRCC, PDAC, CRC, and UC; Part D: is to assess the diagnostic concordance between \[68Ga\]Ga-DPI-4452 Positron Emission Tomography (PET) and the histopathology result of the Indeterminate Renal Mass (IDRM); Part E: is to assess \[68Ga\]Ga-DPI-4452 uptake in each tumour type such as UC, muscle invasive bladder cancer (MIBC), head and neck cancer (H\&N), triple negative breast cancer (TNBC), squamous non-small cell lung cancer (NSCLC), and any other tumor with locally confirmed carbonic anhydrase (CA) IX expression except ccRCC, CRC and PDAC. Phase/Status/Sponsor: Unknown phase; RECRUITING; ITM Oncologics GmbH.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests a drug called MGC028 in adults whose ADAM9-expressing solid tumors are relapsed or refractory, unresectable, locally advanced, or metastatic. - It uses dose escalation to find a safe dose and to describe safety and side effects, including any dose-limiting toxicities and the highest dose that can be given safely. - The trial also aims to learn whether MGC028 can shrink tumors, keep cancer from growing, or control disease in these advanced cancers. - Cancers eligible for participation include NSCLC adenocarcinoma, cholangiocarcinoma, colorectal cancer, and pancreatic cancer with specific prior-treatment criteria; key exclusions include active brain metastases, prior ADAM9-targeted therapy, recent major cancer treatment, organ transplant, infection, and pregnancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors is being studied. Conditions: Solid Tumours, Sarcoma, HNSCC +9 • Eligibility: Inclusion Criteria: 1. Histologically or cytologically confirmed disease, locally advanced or metastatic: For Phase 1a: Solid tumor with a COX2-associated immunosuppressive pathway, for which standard treatment options are…. Goal: The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which side effects of a drug can be tolerated) of OKN4395 alone and in combination with pembrolizumab, OKN4395 and metabolites (broken-down substances) of OKN4395 levels in the blood, and antitumor activity of OKN4395 alone and in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; Epkin.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC is being studied. Conditions: NSCLC • Eligibility: Inclusion Criteria: 1. Patients must understand the requirements and content of the clinical trial and provide a handwritten signed and dated informed consent. 2. Age ≥ 18 years…. Goal: This is a single-arm, phase 2 study to investigate the efficacy and safety of sunvozertinib as neoadjuvant and adjuvant treatment for stage II-IIIB non-small-cell lung cancer patients with EGFR exon20 insertion mutation. Phase/Status/Sponsor: Unknown phase; RECRUITING; Tang-Du Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Using Urine Samples to Identify Lung Cancer is being studied. Conditions: Non Small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Phase I (with NSCLC): Aged 18 to 90 years with histologically proven, previously untreated stage I, II, or IIIA NSCLC °Note: Single, monolateral nodule of…. Goal: The researchers are doing this study to test the ability of an animal biosensor platform (ABP) to detect NSCLC. Participants in this study will either be diagnosed with NSCLC, suspected to have NSCLC, or have not been diagnosed or suspected to have NSCLC. Phase/Status/Sponsor: Unknown phase; RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care is being studied. Conditions: NSCLC, Melanoma • Eligibility: Inclusion Criteria To participate in this study a participant must meet the eligibility of one of the following cohorts: Cohort 1: Cancers beginning initial treatment * One of…. Goal: Tumor genotyping has become an essential biomarker for the care of advanced lung cancer and melanoma, and is currently used to identify patients for treatment with targeted kinase inhibitors like erlotinib and vemurafenib. However, tumor genotyping can be slow and cumbersome, and is limited by availability of tumor biopsy tissue for testing. Phase/Status/Sponsor: Unknown phase; RECRUITING; Dana-Farber Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests impedance cardiography (ICG) to measure heart and blood flow changes during a 6-minute walk test in people with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy and immunotherapy. - It aims to find out whether these cardiac measurements can predict treatment toxicity and survival outcomes. - Participants are adults aged 18 to 75 with untreated, unresectable stage IIIA-IIIC NSCLC and a good performance status. - Key exclusions include mixed histology, pregnancy, life expectancy under 12 weeks, and contraindications to the 6-minute walk test.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluation of Clinical Performance and IVD Test of LifeOS Digital PCR Liquid Biopsy Kits for EGFR T790M Mutation is being studied. Conditions: Non Small Cell Lung Cancer, EGFR T790M • Eligibility: Inclusion Criteria: 1. aged ≥18 years old. 2. Patients with Stage IIIB or IV non-small cell lung cancer (NSCLC) with EGFR mutations. Exclusion Criteria: 1. Pregnant women. 2.…. Goal: Liquid biopsy plays a pivotal role in cancer therapeutics, encompassing critical applications such as early cancer detection, disease progression monitoring, and tailored treatment plan formulation, heralded as a pivotal avenue for the future of cancer management. Established in 2015, LifeOS Genomics Co., Ltd. Phase/Status/Sponsor: Unknown phase; RECRUITING; LifeOS Genomics Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a single-arm, single-center, open clinical study testing GK01, autologous tumor-reactive T cells, given as a cell transfusion to patients with advanced solid tumors. It aims to assess safety and tolerability after GK01 transfusion, and to observe how the cells behave in the body and any early effect on tumors. The trial is for adults aged 18-75 with incurable advanced cancers who have failed standard treatments, including gastric, esophageal, cervical cancers, triple-negative breast cancer, non-small cell lung cancer, and others. It excludes people with active autoimmune disease, immune-related adverse reactions, uncontrolled infections or organ problems, CNS metastases, HIV, hepatitis B or C, pregnancy, or other conditions that make participation unsafe. The study is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests a new PET/CT tracer, 68GaNOTA-Anti-HER2 VHH1, to image HER2 expression in tumors. It is for adults with locally advanced or metastatic breast cancer (cohort 1), other HER2-expressing cancers (cohort 2), and HER2-positive breast cancer planned for neoadjuvant treatment (cohort 3), and the study is currently recruiting. The goal is to learn how repeatable the HER2 imaging is and how tracer uptake matches biopsy results when available, plus whether the tracer adds value in the neoadjuvant setting. Key exclusions include pregnancy or breastfeeding, serious infections or other life-threatening illnesses, inability to consent or cooperate, and, for cohorts 1 and 3, prior participation in this study.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases is being studied. Conditions: NSCLC Stage IV Without EGFR/ALK Mutation • Eligibility: Inclusion Criteria: * Patient must meet all of the following inclusion criteria to be enrolled in this study: 1. Non-small cell lung cancer diagnosed initially through pathological histology.…. Goal: It is planned to carry out a multicenter umbrella study to find the optimal organ combination and the best radioimmunotherapy combination pattern, so as to improve the survival of NSCLC patients with multiple metastases. At the same time, by using multimodal omics data, machine learning will be employed to construct a prediction model for the abscopal effect, and explore the immunoregulation of organ-specific radiotherapy and biomarkers of the abscopal effect. Phase/Status/Sponsor: Unknown phase; RECRUITING; Xinqiao Hospital of Chongqing.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2) is being studied. Conditions: Non-small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. voluntarily sign a written informed consent to participate in the study and be willing and able to comply with study-related visits and procedures; 2. Male…. Goal: The goal of this clinical trial is to test if PLB1001 works well and safely in Non-small cell lung cancer patients with MET exon 14 mutation. The main questions it aims to answer are: * If it is works well in Non-small cell lung cancer patients with MET exon 14 mutation * If it is safety and tolerant in Non-small cell lung cancer patients with MET exon 14 mutation Participants will 1. Phase/Status/Sponsor: Unknown phase; RECRUITING; Beijing Pearl Biotechnology Limited Liability Company.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

APG-2449 in Patients With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer +2 • Eligibility: Inclusion Criteria: 1. Dose exploration stage: non-small cell lung cancer diagnosed by histology and/or cytology and positive for ALK/ROS1 gene fusion (molecular diagnosis confirmed by the investigator) and…. Goal: APG-2449 is a novel, orally active, multi-targeted tyrosine kinase inhibitor, which inhibits FAK, ALK, and ROS1 with nanomolar potencies. In preclinical studies, APG-2449 demonstrated potent antiproliferative activity in various cancer cell lines as a single agent. Phase/Status/Sponsor: Unknown phase; RECRUITING; Ascentage Pharma Group Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients is being studied. Conditions: Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Advanced Non Squamous NSCLC • Eligibility: Inclusion Criteria: 1. Male or female ≥18 years of age inclusive, at the time of signing the informed consent. 2. Capable of giving signed informed consent, which includes…. Goal: The goal of this clinical trial is to learn how roginolisib works in combination with dostarlimab with or without docetaxel in adult patients with advanced non small-cell lung cancer. The main questions it aims to answer are: To compare across the treatment arms the proportion of patients with a reduction in Treg cells To evaluate the safety and tolerability of roginolisib plus dostarlimab, with or without docetaxel Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; iOnctura.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients is being studied. Conditions: Non Small Cell Lung Cancer NSCLC • Eligibility: Inclusion Criteria: * Pathologically or histologically confirmed non-small cell lung cancer (NSCLC) * Age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 *…. Goal: The goal of this observational study is to learn about the relationship between TCM body constitution patterns (called "syndromes") and the effectiveness of EGFR-TKI targeted drugs in patients with lung cancer. Approximately 3000 patients with EGFR-mutant non-small cell lung cancer who are about to start or are already taking EGFR-TKI drugs as part of their regular medical care will be invited to join. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Guangzhou University of Traditional Chinese Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) is being studied. Conditions: Lung Cancer, Non-small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Willing and able to provide written informed consent/assent for the trial. * Be ≥ 18 years of age on day of signing informed consent. *…. Goal: The main purpose of this study is to see whether the combination of two drugs called pembrolizumab and vorinostat can help people with advanced lung cancer. Researchers also want to find out if the combination of pembrolizumab and vorinostat is safe and tolerable. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; H. Lee Moffitt Cancer Center and Research Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer is being studied. Conditions: Non Squamous Non Small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Subject aged between 19-80 at the time of signing the informed consent form, male or female. 2. Histologically or cytologically confirmed non-squamous non-small cell lung…. Goal: The objective of this bridging study is to acquire new drug approval in Korea for camrelizumab (SHR-1210), a drug that has already been approved in China for treatment in patients with histologically or cytologically confirmed advanced or metastatic (Stage IIIB-IV), EGFR/ALK wild-type, non-squamous, non-small cell lung cancer. In this study, subjects with advanced or metastatic, EGFR/ALK wild-type, non-squamous, non-small lung cancer will receive anti-PD-1 antibody therapy of camrelizumab in combination with pemetrexed + carboplatin as first-line treatment for at least 8 cycles (24 weeks). Phase/Status/Sponsor: Unknown phase; RECRUITING; CrystalGenomics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Efficacy and Safety of Microwave Ablation Combined With Huaier Granules in Patients With Inoperable Stage IA Non-Small Cell Lung Cancer: A Prospective, Single-Center, Randomized Controlled Clinical Trial is being studied. Conditions: Non-small Cell Lung Cancer (NSCLC), Huaier Granules, Microwave Ablation • Eligibility: Inclusion Criteria Age: ≥ 18 years old. Diagnosis: Histologically or cytologically confirmed IA stage non-small cell lung cancer (NSCLC) that is inoperable. ECOG Performance Status: 0-2 (Eastern Cooperative…. Goal: This prospective, single-center, randomized controlled clinical trial aims to evaluate the efficacy and safety of microwave ablation (MWA) combined with Huaier granules in patients with inoperable stage IA non-small cell lung cancer (NSCLC). A total of 180 eligible patients will be randomly assigned to receive either MWA alone or MWA combined with Huaier granules. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Xin Ye.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Role of MDSCs and Cancer Stem Cells and Their Cross Talks in NSCLC is being studied. Conditions: Lung Neoplasms, Myeloid-Derived Suppressor Cells, Immunosuppression • Eligibility: Inclusion Criteria: * consecutive patients * lung carcinoma surgically treated by surgery only Exclusion Criteria: * patient receiving chemotherapy, radiotherapy or immunotherapy in the neoadjuvant setting (all objectives)…. Goal: Immunotherapy have revolutionized the field of oncology, but response rates are low and all patients relapse, due to cellular and soluble immunosuppressive mechanisms. MDSC are one of the most important immunosuppressive cells, that also harbour non immunologic functions, favouring cancer invasion. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; University Hospital, Bordeaux.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors is being studied. Conditions: Gastric/Gastroesophageal Junction Cancer, Breast Cancer, Colorectal Cancer +3 • Eligibility: Inclusion Criteria: 1. Aged ≥ 18 years (at time of free and informed consent). 2. Participants must have radiographically confirmed progressive disease (PD) during the last treatment prior…. Goal: This is an open-label, multicenter, Phase 1 study to evaluate the safety, tolerability, PK, and preliminary efficacy of KJ015 administered subcutaneously in participants with HER2-expressing solid tumors. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Shanghai Bao Pharmaceuticals Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC is being studied. Conditions: Non-squamous Non-small-cell Lung Cancer • Eligibility: Inclusion Criteria: * Signed Informed Consent Form (ICF) * Age ≥ 18 years at time of signing ICF * Ability to comply with the study protocol, in the…. Goal: To evaluate the efficacy of tiragolumab with atezolizumab and bevacizumab in previously-treated advanced non-squamous NSCLC. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Georgetown University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC is being studied. Conditions: KRAS Mutation-Related Tumors, Advanced Lung Cancer, Refractory Tumor • Eligibility: Inclusion Criteria: 1. According to the 8th edition of the AJCC/UICC TNM staging system for NSCLC, patients with locally advanced (stage III B/III C), metastatic or recurrent (stage…. Goal: Lung cancer is the most common cause of cancer-related death worldwide. Approximately 85% to 90% of lung cancer cases are non-small cell lung cancer (NSCLC), of which KRAS is one of the most common driver genes, occurring in 25-30% of lung adenocarcinomas and 3-5% of squamous cell carcinomas. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Shanghai Chest Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests Osimertinib plus chemotherapy as the first-line treatment for adults with EGFR mutation-positive NSCLC that is locally advanced or metastatic. - It aims to learn how well this combination works and how safe it is in real-world practice, by looking at investigator-reported progression-free survival and overall survival. - The study is sponsored by AstraZeneca and is currently active but not recruiting. - Eligible participants are adults 18+ with nonsquamous NSCLC and EGFR mutations Ex19del or L858R, at stage IIIB/IIIC or IV, who are considered appropriate for first-line Osimertinib plus chemotherapy by their physician (prior therapies allowed if meeting criteria). - Key exclusions include spinal cord compression or symptomatic brain metastases, a history of interstitial lung disease or active ILD, and other severe uncontrolled conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumors • Eligibility: Inclusion Criteria: * Have measurable disease per Response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) as assessed by the local site investigator. * Have an Eastern…. Goal: Researchers are looking for a better way to treat people who have advanced solid tumors. Advanced solid tumors are types of cancer that may have spread to nearby tissue, lymph nodes, and/or to distant parts of the body and that are unlikely to be cured or controlled with currently available treatments. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Bayer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer is being studied. Conditions: Non Small Cell Lung Cancer, Lung Cancer, Nsclc +2 • Eligibility: Inclusion Criteria: * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.…. Goal: The purpose of this study is to see if Durvalumab and radiation therapy can delay the worsening of disease in patients with non-small cell lung cancer normally treated with sequential chemotherapy followed by radiation therapy. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression is being studied. Conditions: Non-small Lung Cancer • Eligibility: Inclusion Criteria: * Age ≥ 18 years. * Histologically or cytologically metastatic NSCLC (UICC/AJCC TNM Staging System, 9th Edition, Stage Ⅳ). * At least one measurable target tumor…. Goal: This is a multicenter, non-interventional, observational real-world study to evaluate the efficacy and safety of Taletrectinib in ROS1-positive non-small cell lung cancer (NSCLC) following Entrectinib progression. Patients deemed eligible for Taletrectinib by their physicians were enrolled after providing informed consent. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Innovent Biologics (Suzhou) Co. Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC. is being studied. Conditions: Squamous Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Written informed consent must be signed before implementing any trial-related procedures; 2. Age ≥18 years old; 3. Patients with histologically or cytologically confirmed metastatic or…. Goal: This is a prospective, single-arm, multi-center, phase Ⅱ trial to evaluate the efficacy and safety of Polymeric Micelles paclitaxel(pm-Pac), platinum (cisplatin/carboplatin) in combination with Ivonescimab as first-line treatment in metastatic squamous NSCLC patients. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Jiangsu Cancer Institute & Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Overcoming Resistance to EGFR Neutralization by Combination of Monoclonal Antibodies and Novel Cancer Drugs is being studied. Conditions: Non Small Cell Lung Cancer • Eligibility: Inclusion Criteria: * patients aged ≥ 18 years * patients with advanced cancer characterized by amplification/overexpression or activating mutations of the EGFR receptor. * patients who are candidates…. Goal: The study is aimed at patients with advanced cancer and EGFR mutation. Some molecules recently discovered at the level of tumor tissue can influence the response to anti-EGFR drugs. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; IRCCS Azienda Ospedaliero-Universitaria di Bologna.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Construction of a Prognostic and Prediction Model for Perioperative Immunotherapy in NSCLC: a Multi - Omics Perspective is being studied. Conditions: NSCLC Stage IIIA/B, NSCLC Stage II • Eligibility: Inclusion Criteria: * NSCLC, clinical tumor stage II-IIIB * Without EGFR/ALK gene mutation * Patient 18 years or older. * Scheduled for neoadjuvant immunotherapy. * Eastern Cooperative Oncology…. Goal: This research focuses on exploring biomarkers for the application of PD - 1/PD - L1 immune checkpoint inhibitors in the perioperative immunotherapy of lung cancer. Multi - index tests are conducted on tissues prior to treatment, as well as blood samples at baseline and during the treatment course. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Ziming Li.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors is being studied. Conditions: Non Small Cell Lung Cancer, ROS1-positive Non-Small Cell Lung Cancer (NSCLC) • Eligibility: Inclusion Criteria: 1. Age ≥18 years. 2. Histologically or cytologically confirmed locally advanced or metastatic NSCLC or other solid tumor with documented ROS1 rearrangement. 3. Previously received at…. Goal: The Expanded Access Program will provide an alternate mechanism for these patients, who lack satisfactory therapeutic alternatives and cannot participate in a zidesamtinib clinical trial, to access investigational zidesamtinib. Phase/Status/Sponsor: Unknown phase; AVAILABLE; Nuvalent Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive is being studied. Conditions: Advanced Solid Tumor • Eligibility: Inclusion Criteria: * Immunotherapy naive and without access to approved and/or available immune checkpoint inhibitor (ICI) therapy. * Measurable disease per RECIST v1.1. * One of the following…. Goal: This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Incyte Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors is being studied. Conditions: Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma +9 • Eligibility: Key Inclusion Criteria: * Subject has a histologically- or cytologically-diagnosed solid tumor which is advanced or metastatic and which has progressed on or following at least one systemic…. Goal: This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Cybrexa Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations is being studied. Conditions: Local Advanced or Metastatic NSCLC • Eligibility: Inclusion Criteria: 1. Age between 18-75 years old. 2. Histologically or cytologically confirmed diagnosis of NSCLC, locally advanced (Stage IIIB and IIIC according to the 8th edition of…. Goal: This is a multicenter, randomized, open-label, parallel-controlled phase 3 study. This study aims to evaluate the efficacy and safety of JMT101 combined with Osimertinib compared with Cisplatin combined with pemetrexed in participants with local advanced or metastatic non-small-cell lung cancer harboured EGFR 20ins mutation without prior systemic therapy. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Shanghai JMT-Bio Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Chemo-immunotherapy Induction Followed by Hypo-radiotherapy in LA-NSCLC(CHIC) is being studied. Conditions: Lung Cancer, Non-small Cell • Eligibility: Inclusion Criteria: * Be able to provide written informed consent and understand and agree to follow the research requirements and evaluation schedule. * Age \> 18 years at…. Goal: For unresectable locally advanced non-small cell lung cancer (LA-NSCLC), the standard treatment at present is concurrent chemoradiation therapy (CCRT) followed by durvalumab consolidation therapy. The PACIFIC study indicated a significant benefit in progression-free survival (PFS) and overall survival (OS). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Jiangsu Cancer Institute & Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors is being studied. Conditions: Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous) +1 • Eligibility: Inclusion Criteria: * Must be ≥18 years of age * Must have histologically or cytologically confirmed diagnosis as follows: 1. Monotherapy Phase 1: A locally advanced unresectable or…. Goal: This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved agents in participants with RAS-mutated or RAS/MAPK activated advanced or metastatic solid tumors. The dose exploration will identify the candidate recommended Phase 2 candidate optimal dose of IMM-1-104 to further explore the anti-tumor activity of IMM-1-104 as monotherapy and in combination with approved agents in multiple Phase 2a proof-of-concept cohorts in malignancies of interest. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Immuneering Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation is being studied. Conditions: Non-Small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed advanced (stage IIIB) or metastatic (stage IV) NSCLC; * ALK positive with TP53 mutation was confirmed by tissue samples or blood…. Goal: This is a prospective, single-arm, multicenter, phase II study to investigate the efficacy and safety of Ensartinib plus Bevacizumab in metastatic anaplastic lymphoma kinase (ALK)-rearranged Non-Small Cell Lung Cancer (NSCLC) with TP53 mutation. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Sun Yat-sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients is being studied. Conditions: Non-squamous Non-small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. The participant voluntarily joins this clinical research study, understands the research procedures, and is capable of providing written informed consent by signing the Informed Consent…. Goal: Evaluating the Efficacy and safety of Adebrelimab in Combination with Platinum-based Doublet Chemotherapy and SHR-8068 as First-line Therapy for Patients with Advanced or Metastatic NSCLC Carrying STK11/KEAP1/KRAS Mutations Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Shanghai Shengdi Pharmaceutical Co., Ltd.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) is being studied. Conditions: Non-Small-Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Be able to provide a signed and dated, written informed consent. 2. Adults aged ≥18 to 75 years. 3. ECOG performance status 0-1. 4. Predicted…. Goal: This is a phase 2 Study to investigate the safety, tolerability, and anti-tumor activity of golidocitinib in combination with sintilimab as the front-line treatment for patients with metastatic PD-L1 positive non-small cell lung cancer (NSCLC) Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a Phase 1/2 trial testing TC-510, a novel autologous engineered T cell therapy, in adults with advanced cancers that express mesothelin. TC-510 uses T cells modified with a mesothelin-targeting single-domain antibody fused to CD3 and a PD-1:CD28 switch receptor to boost activity against PD-L1–positive cancer cells. Eligible cancers include malignant pleural mesothelioma, serous ovarian adenocarcinoma, pancreatic adenocarcinoma, triple-negative breast cancer, and colorectal cancer, as long as the tumor shows mesothelin expression by immunohistochemistry. Participants must be 18 or older, have 1–5 prior systemic therapies for metastatic or unresectable disease, a good performance status (ECOG 0–1), be fit for leukapheresis, and have adequate organ function; key exclusions are inability to follow study procedures and known non-compliance or drug/alcohol use.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) is being studied. Conditions: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung • Eligibility: Inclusion Criteria: * Has pathologically (histologically or cytologically) confirmed diagnosis of NSCLC * Has Stage IIIA, IIIB, or IIIC NSCLC by American Joint Committee on Cancer Version 8…. Goal: The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced NSCLC. Arms 1 and 2 will be studied in a double-blind design and Arm 3 will be open-label. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Merck Sharp & Dohme LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This expanded access program provides ulixertinib (BVD-523) for compassionate use in people with advanced MAPK pathway–altered solid tumors (including KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations). It is for patients aged 12 and older who have exhausted or not adequately benefited from standard cancer therapies, and it may be given alone or with other tolerable drugs. The goal is to make ULIXERTINIB available and monitor safety and how well patients tolerate it in real-world use. Key exclusions include currently being enrolled in another ulixertinib trial, recent systemic therapy or radiotherapy within defined windows, history of retinal vein occlusion or central serous retinopathy, pregnancy or breastfeeding, significant uncontrolled illness, prior stomach/duodenal surgery affecting absorption, and use of certain interacting medications (strong inhibitors/inducers of CYP1A2, CYP2D6, or CYP3A4).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer is being studied. Conditions: Carcinoma, Non-Small-Cell Lung • Eligibility: Inclusion Criteria: * Diagnosis of stage IV Non-Small Cell Lung Cancer (NSCLC) (histologically or cytologically confirmed stage), without known Epidermal Growth Factor Receptor (EGFR)- or Anaplastic Lymphoma Kinase…. Goal: The purpose of the study is to collect real-life data during the early post-market authorization approval period in Germany. The study aims at describing the outcomes, patient characteristics, safety profile, treatment patterns and patient-reported Quality of Life of first-line treatment with nivolumab plus ipilimumab in combination with two cycles of chemo therapy in participants with confirmed stage IV Non-Small Cell Lung Cancer (NSCLC). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Bristol-Myers Squibb.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer is being studied. Conditions: Non Small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Willing to participate in this trial; fully understand and informed of this trial, and able to provide written informed consent form (ICF). 2. 18-75 years…. Goal: This is a multi-center, randomized, double-blind, phase III study to evaluate the efficacy and safety of CS1001 in combination with platinum-containing chemotherapy versus placebo in combination with chemotherapy in first-line treatment-naive subjects with stage IV non-small cell lung cancer (NSCLC). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; CStone Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PET Imaging of Cancer Patients Using 68Ga-DOTA-Siglec-9 is being studied. Conditions: Acute Myeloid Leukemia, Melanoma, Non Small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Diagnosis of acute myeloid leukemia (AML) and fit for allogeneic hematopoietic stem cell transplantation (alloHSCT), as assessed in the standard operating procedures. * Diagnosis of…. Goal: This is a scientific study to determine expression of vascular adhesion protein 1 (VAP-1) in cancer patients by 68Ga-DOTA-Siglec-9 positron emission tomography/computed tomography (PET/CT) before and after cancer treatment. Phase/Status/Sponsor: Unknown phase; ENROLLING_BY_INVITATION; Turku University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests NGM438 as a standalone treatment and in combination with pembrolizumab for advanced or metastatic solid tumors, to learn about safety and potential effectiveness. It targets adults whose cancer has progressed after other therapies or who could not tolerate them. Eligible participants need adequate bone marrow, kidney, and liver function and a performance status of 0 or 1. They must have recovered from prior treatment side effects to baseline or to CTCAE Grade 1. A key exclusion is prior treatment targeting LAIR1.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI Therapy is being studied. Conditions: Non Small Cell Lung Cancer, T790M, EGFR Gene Mutation • Eligibility: Inclusion Criteria: * Participation in Osimertinib EAP and /or taking / completion therapy with Osimertinib in real clinical practice; * Confirmed diagnosis of IIIB (locally advanced) or IV…. Goal: The purpose of this study is to assess safety of Osimertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with progression during or after therapy with a prior EGFR tyrosine kinase inhibitor (TKI), with confirmed Т790М positive mutation in EGFR gene. Phase/Status/Sponsor: Unknown phase; UNKNOWN; N.N. Blokhin National Medical Research Center of Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents is being studied. Conditions: Cancer, Tumor, Solid, Malignant Neoplasm +7 • Eligibility: Inclusion Criteria: 1. Informed consent signed by the subject prior to conducting study-specific procedures. 2. Male or female subjects ≥ 18 and ≤ 100 years of age. 3.…. Goal: This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805 administered as a monotherapy and in combination with anti-cancer agents in subjects with advanced solid tumors. Phase/Status/Sponsor: Unknown phase; UNKNOWN; OncoResponse, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors is being studied. Conditions: Neoplasms, Neoplasm Metastasis, Non-Small-Cell Lung Cancer • Eligibility: Inclusion Criteria: Molecular Pre-screening Inclusion criteria (Phase II only) 1. The patient must sign the molecular pre-screening Inform Consent to allow for the molecular pre-screening process. All patients…. Goal: First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients with Advanced/Metastatic Solid Tumors Phase/Status/Sponsor: Unknown phase; UNKNOWN; Shanghai EpimAb Biotherapeutics Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901 is being studied. Conditions: Non-squamous Non-small-cell Lung Cancer, Cancer, Lung • Eligibility: Inclusion Criteria: 1. Non-squamous non-small cell lung cancer (NSCLC) confirmed by histology or cytology. 2. Not received prior systemic treatment with stage IV, or recurrent NSCLC. Subjects who…. Goal: To evaluate the efficacy and safety of Pembrolizumab + Pemetrexed in elderly patients with non-squamous non-small cell lung cancer with Programmed cell death (PD) -ligand1 (L1) tumor proportion score (TPS) of less than 50%. Phase/Status/Sponsor: Unknown phase; UNKNOWN; National Hospital Organization Nagoya Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumor, Sarcoma, HNSCC +4 • Eligibility: Inclusion Criteria: * 1\. Age 18\~70 years Part I ; Age 18 years or older (Part II and III ). 2. Histologically or pathologically confirmed diagnosis of locally…. Goal: A Phase I/IIa Study of the Safety and Tolerability of T3011 Administered via Intratumoral Injection in Patients with Advanced Solid Tumors Phase/Status/Sponsor: Unknown phase; UNKNOWN; ImmVira Pharma Co. Ltd.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation is being studied. Conditions: Non-small Cell Lung Cancer, EGFR G719X, EGFR L861Q +1 • Eligibility: Inclusion Criteria: * Provide informed consent prior to any study specific procedures; * 18 -70 years of age; * ECOG PS of 0 to 1 at screening with…. Goal: Furmonertinib, a newly-designed pan-EGFR-TKI with a trifluoroethoxypyridine-based molecule structure, has shown promising clinical efficacy in EGFR Ex19del/L858R/T790M/Ex20ins mutant advanced NSCLC with an acceptable safety profile without new signals from 80mg to 240mg dose level in phase 1-3 clinical trials. Whether EGFR G719X/S768I/L861Q mutation positive advanced NSCLC patients can benefit from first-line furmonertinib 160mg per day has not been reported. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Chongqing University Cancer Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC is being studied. Conditions: NSCLC, Stage III • Eligibility: Inclusion Criteria: 1. Age ≥18 years old and ≤75 years old, both male and female; 2. Histologically or pathologically confirmed patients with stage III (according to the International…. Goal: This is a phase II, open-label, single arm study, aiming to investigate the safety and efficacy of SHR-1701 consolidation therapy after concurrent chemoradiotherapy in inoperable stage III non-small-cell lung cancer (NSCLC) Phase/Status/Sponsor: Unknown phase; UNKNOWN; Shanghai Chest Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Investigate Safety and Tolerability of SH3809 Tablet in Patients With Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumor • Eligibility: Inclusion Criteria: 1. Age between 18 and 75 years inclusive; 2. Histologically or cytologically confirmed advanced malignant solid tumors, eligible patients should be either refractory or intolerant to…. Goal: The primary objective is to determine the safety and tolerability of SH3809 in subjects with advanced solid tumors. The second objective is to evaluate the PK profile and preliminary efficacy of SH3809 in solid tumors. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Nanjing Sanhome Pharmaceutical, Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor is being studied. Conditions: NRG1 Fusion, Pancreatic Cancer, Non Small Cell Lung Cancer +8 • Eligibility: Inclusion Criteria: * Age 18 years or older * At least one evaluable or measurable lesion according to RECIST v1.1 * Patient with advanced metastatic solid tumor with…. Goal: Merus is providing single patient/named access to the HER2/HER3 bispecific antibody, MCLA-128, to patients with advanced NRG1-fusion positive solid tumor under this early access program who are ineligible for an ongoing MCLA-128 clinical trial or have other considerations that prevent access to MCLA-128 through an existing clinical trial. Participating sites will be added as they apply for and are approved for the EAP. Phase/Status/Sponsor: Unknown phase; APPROVED_FOR_MARKETING; Merus B.V..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Interest of Personalized Radiotherapy Dose Redistribution in Patients With Stage III NSCLC is being studied. Conditions: Non-small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Male or female patients, * Age over 18 years and below 75-year-old, * Good general condition: WHO performance status ≤ 1, * Histological evidence of…. Goal: In patients with locally advanced stage III non-small cell lung cancer, the probability of local control remains low (about 17% at 1 year). Concomitant radio-chemotherapy is the standard treatment. Phase/Status/Sponsor: Unknown phase; COMPLETED; Centre Henri Becquerel.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Liquid Biopsy in Advanced Oligometastatic NSCLC Receiving Surgery is being studied. Conditions: Non-small Cell Lung Cancer, Oligometastatic Disease • Eligibility: Inclusion Criteria: * Written informed consent must be obtained from patients and ability for patients to comply with the requirements of the study； * Patients must be a…. Goal: A prospective, observational study that assesses the clinical feasibility of ctDNA-based liquid biopsy in patients with oligometastatic NSCLC receiving surgery. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Guangdong Provincial People's Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation is being studied. Conditions: Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer +4 • Eligibility: Inclusion Criteria: * Diagnosis of cancer with RET activation, who are not eligible for an ongoing selpercatinib clinical trial and are medically suitable for treatment with selpercatinib *…. Goal: Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program. Phase/Status/Sponsor: Unknown phase; APPROVED_FOR_MARKETING; Eli Lilly and Company.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests whether people with advanced solid tumors who have stable disease can stop PD-1/PD-L1 treatment after one year without harming outcomes. It is for patients being treated with PD-1/PD-L1 drugs (like pembrolizumab, nivolumab, atezolizumab, durvalumab, or avelumab). Participants are randomly assigned to stop treatment after about one year or continue treatment until the cancer progresses, to learn the best length of therapy. To join, patients must have at least stable disease on scans within six weeks of randomization; those with progressive disease before randomization or immune-related toxicity that prevents staying on therapy beyond one year are excluded.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation is being studied. Conditions: Non-small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Voluntary agreement to provide written informed consent. * Predicted survival ≥ 12 weeks. * According to UICC/AJCC 8th Edition, histologically and/or cytologically-confirmed, cannot be surgically…. Goal: This study will evaluate the efficacy, safety and pharmacokinetics of RC48-ADC for injection combined with pyrotinib in subjects with local advanced or metastatic non-small cell lung cancer with HER2 mutation. Phase/Status/Sponsor: Unknown phase; UNKNOWN; RemeGen Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation is being studied. Conditions: Non-small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Pathologically confirmed non-small cell lung cancer after surgical resection * Stage II-IIIA disease according to 7th edition of TNM staging * Positive EGFR gene mutation…. Goal: Adjuvant therapy has been proved effective in treating earlier stage or less advanced non-small-cell lung cancer. This study is designed to evaluate the efficacy of icotinib as adjuvant therapy in treating stage II-IIIA non-small cell lung cancer patients with EGFR mutation. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Betta Pharmaceuticals Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC is being studied. Conditions: Non-Small-Cell Lung Cancer • Eligibility: Inclusion Criteria: * Patients must have measurable disease. * Age ≥ 18 years * Adequate renal function * Adequate liver function * Adequate hematological function * Have an…. Goal: The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC Phase/Status/Sponsor: Unknown phase; COMPLETED; BioAtla, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007) is being studied. Conditions: Non-small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Has a histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC) * Has Stage IV NSCLC (American Joint Committee on Cancer \[AJCC 8th…. Goal: The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) in treatment-naïve adults with no prior systemic therapy for their metastatic non-small cell lung cancer (NSCLC) whose tumors have a programmed cell death-ligand 1 (PD-L1) Tumor Proportion Score (TPS) greater than or equal to 1%. The primary study hypotheses are that: 1) the combination of pembrolizumab and lenvatinib is superior to pembrolizumab alone as assessed by Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1); and 2) the combination of pembrolizumab and lenvatinib is superior to pembrolizumab alone as assessed by Overall Survival (OS). Phase/Status/Sponsor: Unknown phase; COMPLETED; Merck Sharp & Dohme LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) is being studied. Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease • Eligibility: Inclusion Criteria: * Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation (phase 2 must be either Non-Small Cell Lung Cancer or Colorectal Cancer) *…. Goal: This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in patients with advanced solid tumors that have a KRAS G12C mutation. Phase/Status/Sponsor: Unknown phase; COMPLETED; Mirati Therapeutics Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast Cancer is being studied. Conditions: Advanced/Metastatic NSCLC, Advanced/Metastatic HER2-negative Breast Cancer • Eligibility: Inclusion Criteria 1. The inclusion criteria for the NSCLC cohort consists of patients with advanced or metastatic (stage IIIB/IIIC or IV) NSCLC diagnosis between January 1, 2015 and…. Goal: This study will identify risk factors for oral mucositis/stomatitis and ocular surface events (OSE) in patients with advanced/metastatic non-small cell lung cancer (NSCLC) and advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Daiichi Sankyo.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases is being studied. Conditions: Non-small Cell Lung Cancer Stage II, Bevacizumab, Immunotherapy +1 • Eligibility: Inclusion Criteria: * Subjects with stage IV non-squamous non-small cell lung cancer (nsqNSCLC) with brain metastases confirmed by histopathology or cytology; * The patient should provide a gene…. Goal: A multicenter, single-arm, open study to evaluate the safety and efficacy of Serplulimab in combination with bevacizumab and first-line chemotherapy in driver negative non-squamous NSCLC patients with brain metastases Phase/Status/Sponsor: Unknown phase; COMPLETED; Sun Yat-sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib is being studied. Conditions: EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Provision of informed consent prior 2. Patients aged 18 years or older 3. Patients with histological confirmation of locally advanced or metastatic NSCLC 4. Patients…. Goal: A multicentre, open-label, single-arm, molecular profiling study of patients with EGFR mutation-positive locally advanced or metastatic NSCLC treated with osimertinib. Phase/Status/Sponsor: Unknown phase; COMPLETED; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients is being studied. Conditions: Small Cell Lung Carcinoma, Non Small Cell Lung Carcinoma, Irinotecan Sensitive Cancers • Eligibility: Inclusion Criteria: * Patients must have histologically or cytologically-confirmed diagnosis of progressive or recurrent malignancy as follows: * Phase II: extensive stage small cell lung cancer with progression…. Goal: The purpose of this study is to determine a well-tolerated dose of Carfilzomib in combination with Irinotecan (Phase 1b portion of the study) in subjects with relapsed small and non-small cell lung cancer or other irinotecan-sensitive cancers and to assess the 6 month survival of relapsed small cell lung cancer patients treated with this combination therapy. \*\*The Phase 1b portion of the study is now complete\*\*. Phase/Status/Sponsor: Unknown phase; COMPLETED; Cancer Research and Biostatistics Clinical Trials Consortium.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT) is being studied. Conditions: NSCLC Stage IIIA/B • Eligibility: Inclusion Criteria: * First diagnosis of histologically and/or cytologically proven and unresectable NSCLC with clinically stage III A and III B * Completion of radiochemotherapy no longer than…. Goal: Targeted Natural Killer (NK) cell based adoptive immunotherapy for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) after radiochemotherapy (RCT) Phase/Status/Sponsor: Unknown phase; COMPLETED; Technical University of Munich.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) is being studied. Conditions: Carcinoma, Non-Small-Cell Lung • Eligibility: Key Inclusion Criteria: * Subjects with Stage IIIB or IV NSCLC (any histology) at the time of study entry * Subjects with histologically or cytologically confirmed diagnosis of…. Goal: Study to evaluate the efficacy and safety of capmatinib as a single-agent treatment for subjects with advanced/metastatic (stage IIIB or IV) non-small cell lung cancer (NSCLC) who had wild-type epidermal growth factor receptor (EGFR wt) (for exon 19 deletions and exon 21 L858R substitution mutations), anaplastic lymphoma kinase (ALK)-negative rearrangement, and mesenchymal epithelial transition (MET) mutations leading to exon 14 deletion (referred to as MET mutation hereafter) and/or MET amplification. Phase/Status/Sponsor: Unknown phase; COMPLETED; Novartis Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL is being studied. Conditions: Solid Tumor, Adult, Head and Neck Cancer, Non Small Cell Lung Cancer +2 • Eligibility: Inclusion Criteria: 1. Histologically or cytologically confirmed diagnosis of metastatic or locally advanced unresectable tumors 2. Patients demonstrating disease progression after treatment with approved therapies that are known…. Goal: The purpose of this first-in-human study of CX-2029 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2029 in adult subjects with metastatic or locally advanced unresectable solid tumors or diffuse large B-cell lymphoma (DLBCL). The antitumor activity of CX-2029 will be evaluated in subjects with head and neck squamous cell carcinoma (HNSCC), DLBCL, non-small cell lung cancer (NSCLC) (squamous cell histology only), or esophageal (esophageal adenocarcinoma \[EAC\], esophageal squamous cell carcinoma \[ESCC\], or gastroesophageal \[GE\] junction) cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; CytomX Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer is being studied. Conditions: Lung Cancer • Eligibility: Inclusion Criteria: 1. Patients must have histologically or cytologically confirmed stage IV non-small cell lung cancer, or recurrent non-small cell lung cancer which is not amenable to curative…. Goal: The goal of Part 1 of this clinical research study is to find the highest dose of (Imbruvica) ibrutinib that can be given to patients with non-small cell lung cancer (NSCLC). The goal of Part 2 of this clinical research study is to learn if the dose of ibrutinib found in Part 1 can help to control the disease. Phase/Status/Sponsor: Unknown phase; COMPLETED; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU) is being studied. Conditions: MET Alterations, Non Small Cell Lung Cancer, METex14 Mutations • Eligibility: Inclusion Criteria: * Patients with histologically or cytologically confirmed locally advanced or metastatic NSCLC (Stage IIIB or IV accordingly to American Joint Committee on Cancer \[AJCC\] classification) at…. Goal: CapmATU study will evaluate time to treatment failure, progression-free survival, overall survival, best response and safety in patients with advanced MET-dysregulated non-small cell lung cancer who received capmatinib as part of an expanded access program. Those outcomes will be correlated to clinical, pathological, and radiological characteristics of patients. Phase/Status/Sponsor: Unknown phase; COMPLETED; Intergroupe Francophone de Cancerologie Thoracique.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Phase I/II Study of PDR001 in Patients With Advanced Malignancies is being studied. Conditions: Melanoma, Non-small Sell Lung Cancer (NSCLC), Triple Negative Breast Cancer +2 • Eligibility: Inclusion Criteria: * Written informed consent must have been obtained prior to any screening procedures * Phase I part: Patients with advanced/metastatic solid tumors, with measurable or non-measurable…. Goal: The purpose of this "first-in-human" study of PDR001 was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of PDR001 administered i.v. as a single agent to adult patients with solid tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; Novartis Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive is being studied. Conditions: Non Small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Squamous or Non-Squamous, non-small cell lung cancer (NSCLC), Stage IIIb/IV (histologically or cytologically confirmed), EGFRm/T790M, who received osimertinib treatment within the Spanish special use medication…. Goal: This is a retrospective, multicenter and observational study of Osimertinib monotherapy treatment in Subjects with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) EGFR-T790M mutation-positive who have received the treatment within the Special Use Medication Program (SUMP) in Spain. Phase/Status/Sponsor: Unknown phase; COMPLETED; Fundación GECP.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive is being studied. Conditions: NSCLC • Eligibility: Inclusion Criteria: * Aged at least 18 years. * Locally advanced or metastatic NSCLC, not amenable to curative surgery or radiotherapy. * Radiological documentation of disease progression after…. Goal: A phase IIb, open-label, single-arm study to assess the safety and efficacy of BPI-7711 capsule in patients with metastatic or recurrent non-small cell lung cancer with EGFR mutation and T790M mutation positive. Phase/Status/Sponsor: Unknown phase; COMPLETED; Beta Pharma Shanghai.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients is being studied. Conditions: Solid Tumor, Breast Cancer, Metastatic Melanoma +1 • Eligibility: Inclusion Criteria: For Phase I, cohorts 1 to 8, of the study: * For patient of Phase I cohort 1, i.e. those patients receiving F16IL2 alone, patients must…. Goal: This Phase Ib/II study is an open label, multicenter study. The study is divided in two parts: Phase I: an open-label, dose escalation study of F16IL2 in combination with paclitaxel for patients with solid tumours, bladder cancer, breast cancer, metastatic melanoma, mesothelioma, NSCLC, prostate cancer and sarcoma amenable to taxane therapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; Philogen S.p.A..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) is being studied. Conditions: Non-small Cell Lung Cancer (NSCLC) • Eligibility: Inclusion Criteria: 1. Patients must have histologic or cytologic diagnosis of advanced/metastatic NSCLC. For those with mixed histology, there must be a predominant histology. 2. Patients must previously…. Goal: The purpose of this study is to determine the safety, tolerability, feasibility and preliminary efficacy of the administration of PBF-509 (Adenosine A2a receptor antagonist) as single agent or in combination with PDR001 (programmed cell death 1 receptor antibody (PD-1 Ab)) to NSCLC patients. Phase/Status/Sponsor: Unknown phase; COMPLETED; Palobiofarma SL.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Drug Concentration Monitoring of Pembrolizumab in Non-Small Cell Lung Cancer Patients is being studied. Conditions: NSCLC • Eligibility: Inclusion Criteria: * Subjects must be \> 18 years and must voluntary sign an informed consent * Treatment-naïve patients with advanced NSCLC receiving immunotherapy alone (pembrolizumab) or combined…. Goal: This observational study explores associations between drug trough-levels and clinical outcomes in Non Small Cell Lung Cancer (NSCLC) patients treated with immunotherapy (pembrolizumab) either alone or combined with chemotherapy. Through-levels of pembrolizumab will be examined in blood samples collected during the first-line treatment period. Phase/Status/Sponsor: Unknown phase; TERMINATED; Oslo University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Immunotherapy in Patient With Poor General Condition is being studied. Conditions: Non-small Cell Lung Cancer Stage IV • Eligibility: Inclusion Criteria: 1. Subjects must have signed and dated an IEC (Independent Ethic Committee) approved written informed consent form in accordance with regulatory and institutional guidelines. This must…. Goal: Immunotherapeutic approaches targeting immune checkpoint proteins PD-1/PD-L1 have recently demonstrated clinical efficacy in several cancer types, and have changed the therapeutic landscape in metastatic melanoma or non-small cell lung cancer (NSCLC). The monoclonal anti-PD-1 antibody nivolumab has been registered by both FDA (Food and Drug Administration) and EMA (European Medicine Agency), for metastatic NSCLC patients, after failure of a prior platinum-based chemotherapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; Intergroupe Francophone de Cancerologie Thoracique.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

TGRX-326 Pharmacokinetic Drug Interaction is being studied. Conditions: Non Small Cell Lung Cancer • Eligibility: Inclusion Criteria: * healthy subject; male or female * Age between 18 and 45 (inclusive) * body mass index (BMI) between 19.0 and 26.0 (inclusive) * agree to…. Goal: This is a drug-drug interaction study for TGRX-326 to evaluate the effects of CYP3A inhibitor/inducer drugs on pharmacokinetic profiles of TGRX-326, an ALK inhibitor indicated for treatment of Non-small cell lung cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Shenzhen TargetRx, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies is being studied. Conditions: Solid Tumors, Cancer • Eligibility: Inclusion Criteria: * The subject has a cytologically or histologically and radiologically confirmed, advanced, recurrent, or metastatic solid tumor of the nine types listed below: * Pancreatic Cancer…. Goal: This is a Phase 2 study to evaluate the efficacy and safety of cabozantinib (XL184) in subjects with selected advanced tumor types. Phase/Status/Sponsor: Unknown phase; COMPLETED; Exelixis.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer is being studied. Conditions: Non-small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Advanced ALK+ or ROS1+ NSCLC And Previously Treated with Chemotherapy or Crizotinib 2. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 to…. Goal: To explore the DLT of ZG0418 for Patients with Advanced ALK+ or ROS1+ NSCLC And Previously Treated with Chemotherapy or Crizotinib, and to determine the MTD or the R2PD. Phase/Status/Sponsor: Unknown phase; COMPLETED; Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluation of Safety and Efficacy of DCVAC/LuCa (Immunotherapy of Lung Cancer) in Patients With Metastatic Lung Cancer is being studied. Conditions: Stage IV Non-small Cell Lung Cancer • Eligibility: Inclusion Criteria: 1. Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) of either adenomatous or squamous cell carcinoma differentiation; mixed tumors will be categorized by the predominant…. Goal: The purpose of the study is to compare efficacy of DCVAC/LuCa + chemotherapy +/- immune enhancers vs. chemotherapy alone in patients with stage IV NSCLC, as measured by progression free survival (PFS). Phase/Status/Sponsor: Unknown phase; COMPLETED; SOTIO a.s..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Osimertinib Study in Indian Patients is being studied. Conditions: Non Small Cell Lung Cancer (NSCLC) • Eligibility: Inclusion Criteria: 1. Patient of either gender and ≥18 years of age 2. Patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an appropriate test, who have…. Goal: This is a prospective, single-arm, multicenter, phase-IV study investigating the safety of osimertinib in Indian adult patients. Phase/Status/Sponsor: Unknown phase; COMPLETED; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The study tests Felmetatug Vedotin (SGN-B7H4V), given alone or with pembrolizumab, to see if it is safe and what side effects it may have in people with advanced solid tumors. It is for adults with locally advanced unresectable or metastatic cancers, including certain ovarian/peritoneal cancers, HER2-negative breast cancer, triple-negative breast cancer, endometrial cancer, some lung cancers, cholangiocarcinoma/gallbladder cancer, and adenoid cystic carcinoma. The trial has five parts to find the right dose, assess safety and activity, study the combination with pembrolizumab, and evaluate safety and efficacy in triple-negative breast cancer. Eligibility includes measurable disease and good functioning (ECOG 0–1) with tumor tissue available; key exclusions are a new cancer within 3 years (with some exceptions), active brain metastases, prior MMAE- or B7-H4-targeting therapy, neuropathy ≥ grade 2, or corneal disease. Status: Terminated.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of SEA-CD40 Given With Other Drugs in Cancers is being studied. Conditions: Melanoma, Carcinoma, Non-Small- Cell Lung • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed unresectable malignancy defined as one of the following: * Cohort 1: Relapsed and/or refractory metastatic melanoma * Uveal/ocular melanoma is excluded…. Goal: This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug. Phase/Status/Sponsor: Unknown phase; COMPLETED; Seagen Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors is being studied. Conditions: Advanced Solid Tumors • Eligibility: Inclusion Criteria: * Participants with histologically or cytologically confirmed locally advanced unresectable, metastatic, or recurrent select solid tumor * Eligible tumor types Non-small cell lung cancer (NSCLC), Urothelial…. Goal: The purpose of this study is to evaluate the safety, tolerability, drug effects, drug levels and preliminary antitumor activity of BMS-986416 when administered alone and in combination with Nivolumab in participants with select advanced solid tumors. Phase/Status/Sponsor: Unknown phase; COMPLETED; Bristol-Myers Squibb.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) is being studied. Conditions: Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer, NSCLC +12 • Eligibility: Inclusion Criteria: * Has a confirmed diagnosis of solid tumor for one of the following types of cancer: previously treated cancers of triple-negative breast cancer (TNBC), non-TNBC HER2-negative…. Goal: This is a study evaluating the efficacy, safety, and pharmacokinetics of zilovertamab vedotin in participants with metastatic solid tumors including previously treated cancers of triple-negative breast cancer (TNBC), non-TNBC human epidermal growth factor receptor 2 (HER2)-negative breast cancer, non-squamous non-small-cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, and platinum-resistant ovarian cancer. The study will evaluate a null hypothesis that the objective response rate (ORR) is ≤5% against the alternative hypothesis that it is ≥20%. Phase/Status/Sponsor: Unknown phase; TERMINATED; VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Bronchial Mapping (GCC 1635) is being studied. Conditions: Thoracic Cancer • Eligibility: Inclusion Criteria: * Patients with primary or metastatic lung lesions to be treated using stereotactic ablative radiotherapy (There is no limitation on the location or number of lesions…. Goal: In order to better understand radiation-induced lung toxicity, the investigator proposes a novel functional avoidance approach that incorporates central as well as peripheral BSS segments in the treatment planning process in order to quantify and account for their respective radiosensitivities. Specifically, the investigator proposes a systematic study that involves acquiring pre- and post-SAbR high-resolution CT and SPECT V/Q scans from lung cancer patients who receive radiotherapy, followed by auto-segmentation of the BSS elements using virtual bronchoscopy. Phase/Status/Sponsor: Unknown phase; TERMINATED; University of Maryland, Baltimore.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

IMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation Therapy is being studied. Conditions: Carcinoma, Non-Small-Cell Lung • Eligibility: Inclusion Criteria: -Patients with locally advanced unresectable non-small cell lung cancer who are treated with IMFINZI for the first time as maintenance therapy after definitive chemoradiation therapy Exclusion…. Goal: To investigate the impact of presence/absence or grade of radiation pneumonitis before starting IMFINZI, on the onset of interstitial lung disease (including radiation pneumonitis) after starting IMFINZI, in the real world in patients with locally advanced unresectable non-small cell lung cancer who are treated with the product as maintenance therapy after definitive chemoradiation therapy. Phase/Status/Sponsor: Unknown phase; COMPLETED; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies is being studied. Conditions: Gastrointestinal Stromal Tumors, Advanced Systemic Mastocytosis, Advanced Cancers • Eligibility: Inclusion Criteria (Escalation and Expansion Phases) Patients must meet the following criteria to be eligible to enroll in the study: 1. Male or female patients ≥18 years of…. Goal: This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with advanced malignancies. The study consists of 2 parts, a dose-escalation phase, and an expansion phase. Phase/Status/Sponsor: Unknown phase; COMPLETED; Deciphera Pharmaceuticals, LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) is being studied. Conditions: Solid Tumors • Eligibility: Inclusion Criteria for dose escalation and expansion phase: * Signed written informed consent * Male or female participants aged greater than or equal to 18 years * Participants…. Goal: This is a Phase 1, open-label, dose-escalation trial of avelumab \[antibody targeting programmed death ligand 1 (anti PD-L1)\] with consecutive parallel group expansion in participants with selected tumor indications. New recruitment is open for all active cohorts. Phase/Status/Sponsor: Unknown phase; COMPLETED; EMD Serono Research & Development Institute, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors is being studied. Conditions: Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC) +2 • Eligibility: Inclusion Criteria: General Inclusion Criteria: * Part A: Patient must have histologically or cytologically confirmed advanced and/or metastatic solid tumor malignancies for which standard curative or palliative measures…. Goal: This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of single agent lomvastomig (RO7121661), an anti PD-1 (programmed death-1) and TIM-3 (T-cell immunoglobulin and mucin domain 3) bispecific antibody, for participants with advanced and/or metastatic solid tumors. The study consists of 2 parts: Dose Escalation (Part A) and Expansion (Parts B1, B2, B3, B4, and B5). Phase/Status/Sponsor: Unknown phase; COMPLETED; Hoffmann-La Roche.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC) is being studied. Conditions: Carcinoma, Non-Small-Cell Lung • Eligibility: Inclusion criteria: * age 18 or older * men and women locally advanced, metastastic and/or recurrent NSCLC with adenocarcinoma histology for which vargatef treatment is indicated according to…. Goal: This observational study will investigate the efficacy and tolerability of Vargatef (Nintedanib) plus docetaxel in daily routine second-line treatment in patients with locally advanced, metastatic or locally recurrent NSCLC. Treatment with Vargatef in eligible NSCLC patients, for whom the treating physician has decided to initiate treatment with Vargatef in second line according to the local label, will be observed for up to 24 months. Phase/Status/Sponsor: Unknown phase; COMPLETED; Boehringer Ingelheim.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents is being studied. Conditions: Non-small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Cohort-specific: Cohort 1- EGFR mutation positive NSCLC patients previously treated with appropriate targeted therapy with progressive and measurable disease per RECIST 1.1 criteria tumor. Cohort…. Goal: Investigators hypothesize that addition of pembrolizumab will enhance the efficacy of carboplatin and pemetrexed in patients with EGFR-mutation-positive NSCLC, or patients with other genetic alterations, and who have disease progression following appropriate targeted therapies. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Michigan Rogel Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations is being studied. Conditions: Non-small Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor (EGFR) Mutations • Eligibility: Inclusion Criteria: * Subject has histologically confirmed locally advanced or unresectable Stage IIIB (not amenable to receive curative treatments such as chemo-radiation)/IV or metastatic NSCLC. * Subject has…. Goal: The objective of this study is to evaluate the bioequivalence of a tablet formulation versus a capsule formulation of ASP8273 following a single dose under fasted condition in subjects with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. The study will also evaluate the safety and tolerability of a tablet formulation as a single dose and a capsule formulation as a single and multiple dose of ASP8273 in subjects with NSCLC harboring EGFR mutations. Phase/Status/Sponsor: Unknown phase; TERMINATED; Astellas Pharma Global Development, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- Milademetan is being tested in adults with advanced or metastatic solid tumors that have wild-type TP53 and MDM2 amplification (copy number ≥ 8) and who are refractory or intolerant to standard therapy. - It is a multicenter, single-arm, open-label basket study designed to evaluate the safety and efficacy of milademetan in this biomarker-defined group. - About 65 patients will be enrolled and treated until disease progression, unacceptable toxicity, or other criteria, with follow-up for progression and survival. - Key exclusions include prior MDM2 inhibitors, certain brain tumors or untreated brain metastases, active HIV or hepatitis infections, and significant cardiovascular disease.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma is being studied. Conditions: NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer, Pancreatic Cancer +7 • Eligibility: Inclusion Criteria: * Male or female patients ≥18 years of age. For Japan only: written consent is necessary both from the patient and his/her legal representative if he/she…. Goal: The purpose of this phase 2 study is to evaluate the efficacy and safety of NIR178 in combination with PDR001 in multiple solid tumors and diffuse large B-cell lymphoma (DLBCL) and further explore schedule variations of NIR178 to optimize immune activation through inhibition of A2aR. Phase/Status/Sponsor: Unknown phase; TERMINATED; Novartis Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC is being studied. Conditions: Non-Small Cell Lung Cancer • Eligibility: Main Inclusion Criteria: 1. Male or female patient ≥ 18 years of age 2. Histologically or cytologically confirmed non-squamous NSCLC 3. EGFR-mutation positive patients must have progressed on…. Goal: The primary purpose of this research study is to evaluate how safe, how well tolerated and how effective a range of doses of L-DOS47 in combination with standard doublet therapy of pemetrexed/carboplatin in patients with Stage IV (TNM M1a and M1b) recurrent or metastatic non-squamous Non-Small Cell Lung Cancer. Phase/Status/Sponsor: Unknown phase; TERMINATED; Helix BioPharma Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations is being studied. Conditions: Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations • Eligibility: Inclusion Criteria: * Provide written informed consent * Histologically confirmed cancers for which no curative therapy exists * Documented HER2 or EGFR exon 18 mutation * Participants must…. Goal: This is an open-label, multicenter, multinational, Phase 2 basket study exploring the efficacy and safety of neratinib as monotherapy or in combination with other therapies in participants with HER (EGFR, HER2) mutation-positive solid tumors. Phase/Status/Sponsor: Unknown phase; TERMINATED; Puma Biotechnology, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

LITT and Pembrolizumab in Recurrent Brain Metastasis is being studied. Conditions: Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC) +12 • Eligibility: INCLUSION CRITERIA 1. Histologic confirmation of primary cancer approved by the FDA for treatment with an immune-checkpoint inhibitor 2. At least one metastatic lesion has had prior SRS.…. Goal: This is an open-label, historically controlled pilot study investigating the immune effect of Laser Interstitial ThermotHerapy (LITT)+ pembrolizumab in adult patients with a primary cancer approved by the FDA for treatment with an immune-checkpoint inhibitor who have recurrent brain metastasis after prior stereotactic radiosurgery (SRS). Phase/Status/Sponsor: Unknown phase; TERMINATED; University of Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors is being studied. Conditions: Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors • Eligibility: Inclusion Criteria: * Histological diagnosis of locally advanced (primary or recurrent) or metastatic solid tumors that are not amenable for treatment with curative intent in adult patients with:…. Goal: Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), hormone receptor positive (HR+) breast cancer, recurrent platinum sensitive ovarian cancer, urothelial cancer (UC), and castration resistant prostate cancer (CRPC). Phase/Status/Sponsor: Unknown phase; TERMINATED; Pfizer.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

RTX-224 Monotherapy in Patients With Solid Tumors is being studied. Conditions: Non Small Cell Lung Cancer, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma +2 • Eligibility: Inclusion Criteria: * Signed written informed consent obtained prior to study procedures Patients ≥18 years with an ECOG of 0 or 1 * R/R, or locally advanced, unresectable,…. Goal: This is an open-label, multidose, first-in-human (FIH), Phase 1/2 study of RTX-224 for the treatment of patients with relapsed or refractory (R/R), or locally advanced solid tumors. Phase/Status/Sponsor: Unknown phase; TERMINATED; Rubius Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) is being studied. Conditions: Solid Tumors, Advanced Malignancies, Metastatic Cancer • Eligibility: Inclusion Criteria: * Willingness to provide written informed consent for the study. * Willingness to undergo a pretreatment and on-treatment tumor biopsy to obtain tumor tissue. * Eastern…. Goal: This is an open-label, Phase 1/2 study in subjects with advanced or metastatic solid tumors. The study has three separate treatment groups where separate epigenetic agents are evaluated with an immunotherapy combination. Phase/Status/Sponsor: Unknown phase; TERMINATED; Incyte Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma is being studied. Conditions: EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC • Eligibility: Inclusion Criteria: 1. Patients (male/female) must be ≥18 years of age. 2. Chemotherapy naïve, non-squamous NSCLC, stage IIIB/C (not amenable to radical therapy) or IV. Patients who have…. Goal: ETOP 15-19 ABC-lung is an international, multi-centre open-label, randomized phase II trial with two non-comparative parallel arms of atezolizumab plus bevacizumab with carboplatin-paclitaxel (Arm A) or atezolizumab, bevacizumab and pemetrexed (Arm B) in patients with stage IIIB-IV non-squamous non-small cell lung cancer (NSCLC) harbouring EGFR mutations after failure of standard EGFR tyrosine kinase inhibitors (TKIs). Phase/Status/Sponsor: Unknown phase; COMPLETED; ETOP IBCSG Partners Foundation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.